A research reference on tesamorelin dosage: the fixed 2 mg daily dose used across the phase 3 trials, why the three approved formulations list different milligram figures, the sub-hour half-life, and the reconstitution math. A literature overview, not medical advice.
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone — GRF(1–44) carrying a trans-3-hexenoyl group on the N-terminal tyrosine, a modification that blunts dipeptidyl peptidase-4 cleavage. It is the only GHRH analog to have completed a phase 3 program and reached FDA approval (2010, for excess visceral abdominal fat in HIV-associated lipodystrophy), which makes its dosing record unusually concrete for this category. What follows is a literature overview — the fixed doses studied, the reconstitution arithmetic, and the very short half-life that shapes both. It is not a protocol and not medical, veterinary, or human-dosing advice.
Incretin analogs made stepwise titration the default mental model for peptide dosing. Tesamorelin does not follow it — its registrational program used one fixed daily dose from the first injection onward.
Falutz and colleagues (New England Journal of Medicine, 2007) randomized 412 participants to 2 mg subcutaneously once daily or placebo for 26 weeks. CT-measured visceral adipose tissue fell 15.2% on tesamorelin and rose 5.0% on placebo; a 26-week extension carried the separation to roughly 18% at 52 weeks. Stanley and colleagues held the dose at 2 mg daily in both of their subsequent trials — six months in JAMA (2014), reporting a mean visceral adipose change of −34 cm² versus +8 cm² on placebo, and 12 months in The Lancet HIV (2019) against hepatic fat fraction, where the absolute effect size was −4.1%, roughly a 37% relative reduction from baseline.
Two features matter more than the milligram number. No dose ladder was established, so the record shows what a fixed 2 mg exposure produced, not what a smaller or larger one would. And the effect was not durable: participants re-randomized to placebo in the extension phase re-accumulated visceral fat — the pharmacology is continuous-exposure-dependent, not restorative.
The approved daily dose has been stated three different ways. All three target comparable exposure; the differences are formulation.
| Formulation | Vial strength | Reconstitution | Daily dose | Injection volume |
|---|---|---|---|---|
| EGRIFTA (original) | 1 mg × 2 vials | 2.2 mL diluent into vial 1, transferred into vial 2 | 2 mg | 2 mL |
| EGRIFTA SV | 2 mg | 0.5 mL sterile water (4 mg/mL) | 1.4 mg | 0.35 mL |
| EGRIFTA WR (F8, approved March 2025) | multi-dose vial | 1.3 mL diluent (8 mg/mL) | 1.28 mg | 0.16 mL |
The descending sequence — 2 mg, 1.4 mg, 1.28 mg — reflects successive reformulations with improved delivery, not a downward revision of the pharmacological target. The useful takeaway: the milligram figure is a property of the formulation, not of the molecule. A milligram of research-grade lyophilate is not interchangeable with a milligram of a finished drug product whose fill, excipients, and bioavailability were characterized in a filing.
After a single subcutaneous dose of EGRIFTA SV, the labeled mean elimination half-life is roughly 8 minutes in healthy subjects, with median time to peak near 0.15 hours. After 14 consecutive days of dosing it lengthens to approximately 26 minutes in healthy subjects and 38 minutes in participants with HIV. Absolute subcutaneous bioavailability is reported as under 4%.
Tesamorelin is not present long enough to act as a sustained signal; it triggers an endogenous GH pulse at pituitary GHRH receptors, and the downstream IGF-1 response — which persists far longer than the parent peptide — is what trials tracked as the pharmacodynamic readout. The ghrelin-receptor secretagogues covered in our category guide and in ipamorelin dosage follow the same logic at a different receptor.
Research-grade tesamorelin ships lyophilized. The arithmetic is the same as for any peptide: concentration = peptide mass ÷ diluent volume. Worked for the 20 mg vial:
The lower concentration is easier to measure accurately at small volumes. Full method and conversions are in dosing math and reconstitution 101.
Post-reconstitution stability is formulation-specific and does not generalize. EGRIFTA SV labeling directs immediate use with the remainder discarded and no freezing or refrigeration; the F8 formulation was engineered for weekly reconstitution, one vial covering seven daily doses at room temperature. A generic research lyophilate carries neither dataset, so no equivalent shelf-life claim can honestly be made about it.
Approved labeling specifies subcutaneous injection into the abdomen with site rotation; time of day is not specified. The notable exception in the literature is the cognition work of Baker and colleagues, which used 1 mg once daily roughly 30 minutes before bedtime for 20 weeks in 152 adults aged 55–87 across healthy and mild-cognitive-impairment cohorts, reporting a favorable effect on overall cognition with the clearest signal in executive function. That bedtime timing reflects the nocturnal dominance of endogenous GH pulsatility rather than any property of the peptide.
Beyond these, the record is narrow — no dose-ranging study, and essentially no controlled data outside HIV-associated lipodystrophy and the cognition cohorts. Precise doses quoted for other applications are extrapolation, not evidence. For mechanism, see our tesamorelin research overview.
Why do the approved tesamorelin products list three different daily doses? Each is a different formulation. Original EGRIFTA used 2 mg, EGRIFTA SV uses 1.4 mg, EGRIFTA WR uses 1.28 mg. Intended exposure is comparable; the milligram figure changes with fill concentration and delivery efficiency.
What half-life should a literature comparison assume? Roughly 8 minutes after a single subcutaneous dose, extending to about 26–38 minutes after repeated daily administration, with subcutaneous bioavailability under 4%. The IGF-1 response persists much longer than the peptide itself.
How is concentration calculated from a 20 mg vial? Divide mass by diluent volume: 20 mg in 2 mL is 10 mg/mL, 20 mg in 4 mL is 5 mg/mL. Convert to insulin-syringe units by remembering 100 units equals 1 mL. See dosing math.
Has tesamorelin been studied at doses other than 2 mg daily? Sparsely. The main published example is the 1 mg pre-bedtime dose in the 20-week cognition trial. There is no formal dose-ranging program in the public record, so the space between and beyond those figures is uncharacterized.
Can reconstituted tesamorelin be stored? That depends on the formulation; no general answer applies. Research-grade lyophilate has no comparable stability data behind it.
